Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact

Conversations with Giants in Medicine

Bruce Beutler

A legend within the field of innate immunity, Dr. Bruce Beutler of the University of Texas Southwestern Medical School is best known for two seminal discoveries: identifying mouse tumor necrosis factor and discovering Toll-like receptor 4, the receptor for lipopolysaccharide. With this discovery, later rewarded with the 2011 Nobel Prize in Physiology or Medicine, we finally understood how immune cells could recognize and react to bacteria. Watch the full interview for many more stories on developing etanercept, searching landfills for sequencers, and falling in love with genetics.


John Oates

Dr. John Oates of Vanderbilt University was central in launching the field of clinical pharmacology and gave life to the concepts of first-pass drug metabolism and interindividual variation in the way humans process drugs. Dr. Oates also made seminal discoveries on the metabolism, biosynthesis, and pharmacology of eicosanoids. Watch the full interview for many more stories about testifying before Congress and Dr. Oates' love of sailing.


Christine Seidman

Dr. Christine Seidman of the Harvard Medical School has uncovered the genetic basis of many human cardiovascular disorders, from cardiomyopathy and heart failure to congenital heart malformations. In this interview, she speaks about her early intrigue with atrial natriuretic factor and her more current gene-intensive investigations. She also shares many more stories about her interest in the ear, an early inspirational patient, and her thoughts on work-life balance.


Stephen O’Rahilly

Professor Stephen O’Rahilly’s research has led to an increased understanding of the genetic causes of human obesity and insulin resistance. Using modern biochemical approaches and classical clinical observation in humans with profound metabolic disorders, O’Rahilly, from the Departments of Medicine and Clinical Biochemistry at the University of Cambridge, has shown that a person’s appetite and feeding behavior can be linked to specific genes. His work has challenged long-held dogmas and led to new treatment avenues. The full interview includes many more stories about how you can learn more from reading Chekhov than medical school and why he has stayed in Cambridge all these years.


Bruce Spiegelman

More than almost any other scientist in the field of obesity and metabolism research, the work of Bruce Spiegelman, from the Dana-Farber Cancer Institute and Harvard Medical School, has informed potential targets for drug discovery that could burn fat and even turn fat into muscle. He was the first to suggest that inflammation underscores insulin resistance, and also the first to find the key regulator of adipogenesis, PPAR-γ.

  • ← Previous
  • 1
  • 2
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • Next →
Advertisement
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts